BIO-TECHNE Corp Asset Impairment Charges
BIO-TECHNE Corp (TECH) reported Asset Impairment Charges of $546.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2021-11-08
- BIO-TECHNE Corp asset impairment charges for the quarter ending 2021-09-30 was $546.00K.
- BIO-TECHNE Corp asset impairment charges for the quarter ending 2020-09-30 was $0.00.
- BIO-TECHNE Corp asset impairment charges for the quarter ending 2018-03-31 was $16.25M.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 9 month |
|---|---|---|
| 2021-09-30 | $546.00K 10-Q · filed 2021-11-08 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | |
| 2018-03-31 | $16.25M 10-Q · filed 2019-05-07 | $16.23M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |